Charged Alpha
CHARGED ALPHA · RESEARCH PACKET
Companion to the Q3 2026 earnings episode · published November 15, 2026

HIMS: Bigger Sales, Thinner Margins—What Do Shareholders Keep?

Hims & Hers Health · NYSE: HIMSQuarter ended September 30, 2026Results November 9, 2026 (3:05 p.m. CT)
HOLDUncertainty: High
Fair value (base)$17.10range $0.00–$46.54
Price, Nov 13 close$19.73-13% to base
Probability-weighted$20.18+2% to weighted present value

Base current fair value is about $17.10. Growth must convert into gross contribution and funded owner cash before new buying is attractive.

Layer 1 · fast

The 60-second read

Q3 revenue$890.4mUp49% year over year
Gross margin57%Versus74% in Q3 2025
Subscribers2.788mUp13% year over year
Q3 free cash flow$26.0mVersus$79.4m in Q3 2025

Five things to know

  1. Revenue growth outpaced gross-profit growth. Revenue rose to $890.4 million, up 49%, while gross profit rose about 15% to $509.2 million. Gross margin fell to 57% from 74%.
  2. Branded mix changes the economics per dollar sold. Branded products can increase reported sales while leaving less gross profit to cover marketing, service and technology. Our base assumes gradual margin recovery.
  3. Subscriber metrics are not disclosed cohort retention. Ending subscribers rose 13% to 2.788 million. The aggregate count gives no separate retention, acquisition cost or contribution data for individual customer cohorts.
  4. Acquisition claims and share awards matter to common value. September 30 acquisition claims totaled $733.9 million. The valuation schedules assumed settlements and includes share awards in the ownership bridge.
  5. A feasible upside case still requires cash and financing evidence. Free cash flow was $26.0 million, down from $79.4 million. The base explicitly models assumed equity financing and includes the associated shares in per-share value.
Layer 1 · the call

Three scenarios, one probability-weighted number

Present common-equity scenario values · Subjective scenarios; severe failure recovery is zero
BearBear: $0.00$0.00BaseBase: $17.10$17.10BullBull: $46.54$46.54
BearBear: $0.00$0.00BaseBase: $17.10$17.10BullBull: $46.54$46.54
Show the data
ItemUSD/share
Bear0.00
Base17.10
Bull46.54
ScenarioProbabilityPresent valuevs $19.73What has to happenThe arithmetic
Bear25%$0.00−100%Severe margin, regulation and funding failure2036 revenue $4.71bn; gross margin 56%.
Base50%$17.10−13%Gradual contribution recovery with explicit equity funding2036 revenue $8.62bn; gross margin 61%.
Bull25%$46.54+136%Stronger retention, customer growth and operating leverage2036 revenue $12.96bn; gross margin 65%.
Subjective analyst probabilities, not calibrated odds. The main model base leads the call.
Layer 1 · falsifiable

Signposts: what would change our mind

SignpostNow (Q3 2026)Green ifRed ifNext check
Q4 revenue$875–895m guideSales with stronger gross contributionSales growth without contributionNext Q4 release; date unverified
Q4 adjusted EBITDA$70–90m guideImprovement backed by cash conversionLarge exclusions or weak cash persistNext Q4 release; date unverified
Subscriber economics2.788m end-Q3Recovery with efficient acquisitionSubscriber weakness and heavier spendQ4 2026 / early2027 reporting
Acquisition funding$733.9m Sep30 claimsSettlement preserves liquidity and ownershipLarger equity need or cash pressureQuarterly through2028; model timing assumed
FTC process≈$60m accrualClearer bounded cash/operating consequencesHigher loss or operating restrictionsJan14,2027 scheduled hearing; may change
Debt and revolver$1.4025bn note principalFunding secured before maturitiesCostly refinancing or reduced flexibilityRevolver Feb18,2028; notes2030/2032

Update actual customer, cash and ownership evidence together; a headline alone does not settle the thesis.

Stock price and investment thesis

Our call is HOLD at the November 13, 2026 regular-session close of $19.73. Base present fair value is approximately $17.10 per common share. That is an estimate of current value, not a one-year price target. The stock has meaningful upside if customer economics improve more than our base assumes, but the current price does not provide enough protection against the acquisition, financing and regulatory risks to justify fresh buying on our assumptions. Business quality and investment attractiveness are separate judgments.

The decisive question is whether a larger customer relationship creates more sustainable cash per share. Quarterly revenue grew 49%, yet gross profit grew approximately 15%. The shift toward branded weight-loss products and a larger international footprint can increase sales while reducing the percentage of each sale available to fund marketing, support, technology and shareholders. We do not assume that the former gross-margin structure returns automatically, and we do not freeze the present weakness forever.

The main model follows average subscribers and revenue per average subscriber into gross profit, cash operating costs, investment and owner economics. It explicitly recognizes acquisition obligations, outstanding awards and assumed funding. Its base gives about $17 of current value; subjective scenario weights produce about $20. These are different outputs. We do not replace the main model with the weighted number merely because the latter sits closer to the market price.

The conditional base value at December 31, 2027 is roughly $19.97, assuming no dividends. That represents approximately 1% total upside from the reference quote, below our 12% annual equity-return requirement. This horizon value is calculated from the remaining operating business and the projected cash and claim balances, not by multiplying current fair value by a required return. Neither number guarantees a future trading price.

Quarterly financial scorecard

Hims reported $890.373 million of Q3 revenue, compared with $598.976 million in the prior-year quarter. Gross profit increased from $442.058 million to $509.199 million. The difference between sales growth and gross-profit growth is central: revenue rose approximately 48.6%, while gross profit rose approximately 15.2%. Gross margin was reported as 57%, down from 74%. Those margins are rounded issuer figures; dollar calculations use the reported unrounded financial-statement amounts.

The company reported a $66.146 million operating loss and a $33.040 million net loss. Adjusted EBITDA was $82.388 million versus $78.365 million. Adjusted EBITDA excludes several economically important costs, including stock compensation and acquisition-related expenses. A reconciliation is useful for analyzing operations, but the adjustment label does not determine whether an item costs shareholders money. Stock compensation must be recognized through either cash economics or ownership dilution, and acquisition obligations must be funded.

Operating cash flow was $65.393 million in the quarter. The company's free-cash-flow definition subtracts property, equipment and intangible purchases plus software investment, producing $25.974 million. A year earlier, quarterly free cash flow was $79.364 million. Nine-month free cash flow was only $10.813 million, after $107.997 million of capital spending and software investment. The nine-month view avoids treating seasonal working-capital timing as a permanent run rate.

The tables below preserve the distinction between reported GAAP results, reported non-GAAP measures and calculated growth rates. Our forecast cash flow is a separate economic FCFF measure, with new-grant compensation and normalized tax treatment. It should not be presented as if the issuer reported or guided that measure. A persuasive thesis must explain how the company moves from these actual figures toward the stronger modeled cash path.

Revenue and gross profit · Reported Q3 2026 vs Q3 2025; USD millions
2025 revenue2025 revenue: $599.0M$599.0M2026 revenue2026 revenue: $890.4M$890.4M2025 gross profit2025 gross profit: $442.1M$442.1M2026 gross profit2026 gross profit: $509.2M$509.2M
2025 revenue2025 revenue: $599.0M$599.0M2026 revenue2026 revenue: $890.4M$890.4M2025 gross profit2025 gross profit: $442.1M$442.1M2026 gross profit2026 gross profit: $509.2M$509.2M
Show the data
ItemUSD millions
2025 revenue598.98
2026 revenue890.37
2025 gross profit442.06
2026 gross profit509.20
Quarterly gross margin · Rounded issuer gross margins
Q3 2025Q3 2025: 74.0%74.0%Q3 2026Q3 2026: 57.0%57.0%
Q3 2025Q3 2025: 74.0%74.0%Q3 2026Q3 2026: 57.0%57.0%
Show the data
ItemPercent
Q3 202574.00
Q3 202657.00
Operating cash and free cash flow · Reported Q3 2026; no quarterly annualization
Operating cashOperating cash: $65.4M$65.4MCapital/software spendingCapital/software spending: $39.4M$39.4MFree cash flowFree cash flow: $26.0M$26.0M
Operating cashOperating cash: $65.4M$65.4MCapital/software spendingCapital/software spending: $39.4M$39.4MFree cash flowFree cash flow: $26.0M$26.0M
Show the data
ItemUSD millions
Operating cash65.39
Capital/software spending39.42
Free cash flow25.97

Customer economics and business environment

Hims is best analyzed as a healthcare subscription and commerce platform, not a drug developer with a patent portfolio. It connects customers with clinicians, treatment options, fulfillment and continuing support. Its customer relationship can be valuable when it lowers friction, improves appropriate follow-up and makes repeated purchases more efficient. The economics depend on retention, acquisition spending, product mix and the portion of treatment revenue retained after drug and service costs.

Domestic revenue was $657.089 million, up 21%; international revenue was $233.284 million, up 321%. These geographic comparisons are not organic-growth measures. Eucalyptus contributed approximately 15% of consolidated Q3 revenue, according to the acquisition note. The transaction expanded the international customer base, but it also created substantial deferred and contingent claims. Acquired growth belongs in the operating forecast and its purchase obligations belong in the equity bridge; counting only the first half would overstate value.

End-period subscribers were 2.788 million, up 13%. Monthly revenue per average subscriber was $105, versus $81. The issuer defines this as total revenue divided by average subscribers and months in the period. Total revenue includes one-time purchases; the average subscriber denominator is the average of beginning and ending subscriber counts. Therefore this is not a pure subscription price, a retention rate or proof that pricing rose 30%. Higher-priced branded drugs and acquisition mix affect it.

Manufacturers retain important economic power through product supply, contracts and price. Better access can strengthen the platform's appeal while compressing its margin. Competition also includes other direct-care platforms, established healthcare channels and manufacturer-supported access pathways. We do not assume that customer convenience automatically produces an enduring monopoly or that all drug spending is high-margin platform revenue. The useful question is whether the relationship improves lifetime contribution after marketing and service costs.

Geographic revenue · Reported Q3 2026; growth includes acquisitions
United StatesUnited States: $657.1M$657.1MInternationalInternational: $233.3M$233.3M
United StatesUnited States: $657.1M$657.1MInternationalInternational: $233.3M$233.3M
Show the data
ItemUSD millions
United States657.09
International233.28
End-period subscribers · Reported counts; not average customers or gross additions
Q3 2025Q3 2025: 2.52.5Q3 2026Q3 2026: 2.82.8
Q3 2025Q3 2025: 2.52.5Q3 2026Q3 2026: 2.82.8
Show the data
ItemMillions
Q3 20252.47
Q3 20262.79

From contribution to owner cash

Gross profit less marketing is a practical, limited checkpoint. It increased from approximately $209.908 million to $261.919 million. This is not a disclosed segment profit measure, EBITDA or free cash flow: it is a calculated contribution before other operating costs. It nevertheless shows that lower gross margin did not erase every benefit of growth. The platform had more gross profit dollars left after marketing than a year earlier.

Marketing expense was $247.280 million, or approximately 27.8% of revenue. Dividing marketing by net subscriber growth would not produce a valid customer acquisition cost. Net growth combines gross additions and churn, and reported marketing includes more than direct acquisition spending. The company does not supply the full cohort retention, gross-addition and lifetime-value data needed for a robust cohort model in the materials reviewed. We leave those measurements undisclosed rather than manufacture precise LTV/CAC ratios.

Our base uses average subscribers of 3.15 million in 2027, rising to 6.3 million in 2036. Revenue per average subscriber increases gradually from $105 to $114 per month. Together, those drivers generate $3.969 billion and $8.618 billion of revenue in the respective years. Gross margin recovers from 57% to 61%, marketing intensity falls to 20%, and cash support, technology and administrative costs gain scale. These are author assumptions, not guidance.

The model charges new future compensation grants economically at 4% of revenue. It also deducts capital expenditure, incremental working capital and normalized taxes. Existing awards are handled in the share bridge, so their future accounting expense is excluded from cash operating costs. Depreciation is excluded from cash expense ratios and enters EBIT separately before taxes; capex is then deducted in FCFF. This prevents both pretending asset investment is free and subtracting the same cost twice. The strong later cash path is an execution requirement, not a guaranteed outcome.

Gross profit less marketing · Computed contribution before other operating costs
Q3 2025Q3 2025: $209.9M$209.9MQ3 2026Q3 2026: $261.9M$261.9M
Q3 2025Q3 2025: $209.9M$209.9MQ3 2026Q3 2026: $261.9M$261.9M
Show the data
ItemUSD millions
Q3 2025209.91
Q3 2026261.92
Base revenue path · Author customer and revenue-per-subscriber assumptions
20272027: $3,969.0M$3,969.0M20302030: $5,637.6M$5,637.6M20332033: $7,326.0M$7,326.0M20362036: $8,618.4M$8,618.4M
20272027: $3,969.0M$3,969.0M20302030: $5,637.6M$5,637.6M20332033: $7,326.0M$7,326.0M20362036: $8,618.4M$8,618.4M
Show the data
ItemUSD millions
20273,969.00
20305,637.60
20337,326.00
20368,618.40
Base economic FCFF · After new-grant costs, tax and reinvestment; differs from issuer FCF
20272027: −$61.2M−$61.2M20302030: $318.5M$318.5M20332033: $709.2M$709.2M20362036: $993.6M$993.6M
20272027: −$61.2M−$61.2M20302030: $318.5M$318.5M20332033: $709.2M$709.2M20362036: $993.6M$993.6M
Show the data
ItemUSD millions
2027−61.23
2030318.48
2033709.22
2036993.60

Independent acquisition reference

The June 2026 Eucalyptus acquisition provides an independently motivated reference for the scale of operating value. The purchase price for accounting purposes was $968.539 million. Its contribution was approximately 15% of consolidated third-quarter revenue, implying roughly $133.6 million for that quarter. Annualizing that quarter purely as a comparison denominator gives approximately $534.2 million. Consideration divided by that denominator is approximately 1.81 times.

Our base Hims enterprise value divided by Hims' own Q3 revenue annualized is approximately 1.69 times. This comparison does not establish that the stock is worth an exact transaction multiple. Eucalyptus consideration is accounting purchase price, not independently verified enterprise value. The filing does not give every adjustment necessary to convert it into a clean market-observed EV benchmark. Geography, product mix, acquisition control, acquired cash and debt, and post-combination employment payments can change comparability materially.

The useful conclusion is modest: the main model's operating-value scale is not obviously detached from the recent transaction context. The comparison does not validate the equity target, since Hims' own debt, acquisition claims and share structure still matter. We never average the transaction ratio with the DCF to force agreement. A single acquired company cannot substitute for a well-matched public peer set or observed customer lifetime economics.

For quality assessment, watch whether the platform can convert relationships into recurring gross contribution while reducing the need to reacquire customers. Management's discussion of improved engagement and retention is a hypothesis to test against subsequent disclosure. Without measured cohorts, confidence should remain limited. Evidence of durable cross-specialty retention, better service outcomes and lower marketing cost per retained gross-profit dollar would strengthen the thesis. Growth purchased with consistently heavier spending would weaken it, even if revenue targets were met.

Transaction reference versus main-model scale · Consideration/revenue is NOT equivalent to verified EV/revenue; comparison only
Eucalyptus consideration / run rateEucalyptus consideration / run rate: 1.81.8HIMS model EV / run rateHIMS model EV / run rate: 1.71.7
Eucalyptus consideration / run rateEucalyptus consideration / run rate: 1.81.8HIMS model EV / run rateHIMS model EV / run rate: 1.71.7
Show the data
ItemTimes quarterly revenue annualized
Eucalyptus consideration / run rate1.81
HIMS model EV / run rate1.69

Cash, debt, acquisitions and ownership

At September 30, cash and equivalents were $605.604 million and short-term investments were $106.617 million. The $712.221 million combined total is not all excess cash. Our model retains $125 million as required operating liquidity. That reserve is an operating asset, not a second penalty on cash already consumed by forecast losses. Incremental working capital is modeled separately as the business expands.

Convertible note principal was $1.4025 billion, compared with $1.367393 billion carrying value. The $1 billion tranche matures May 15, 2030, and the $402.5 million tranche June 1, 2032. Both have zero regular coupons. Face principal is deducted once from enterprise value; no interest expense or duplicate principal repayment is also subtracted from FCFF. Capped-call protection offsets conversion exposure up to the contractual caps, with net exposure above those caps included in the share-value solver. Operating leases remain operating costs, so their liabilities are not deducted again.

Deferred acquisition and earn-out claims totaled $733.864 million, including $565.233 million current. These are separate from note debt and cannot be ignored. The explicit Q4 bridge uses the issuer's revenue and adjusted-EBITDA guidance to estimate economic cash after compensation, tax and investment. It splits 44 days through November 13 from 48 remaining days. It assumes a $125 million acquisition payment on December 18, reducing cash and claims together. That date and amount are planning assumptions, not assertions of an announced payment schedule.

The base assumes $250 million of gross equity funding on November 16 at $19.73, with 3% fees and about 12.67 million new shares. This is unannounced hypothetical financing. Remaining current acquisition claims are phased through 2027 and the remaining balance through 2028. The resulting minimum cash is approximately $156.6 million, above the $125 million floor. The bull's minimum is approximately $138.1 million without new equity. The severe bear cannot finance its losses. Different settlement timing, prices or operating cash would change these results; the revolver is a contingency, not free permanent capital.

There were no repurchases during the first nine months. Common shares rose by 7.153 million from December 31 to September 30. We count both economic share classes, unvested awards and in-the-money options with exercise proceeds. Existing awards are counted once; new-grant costs are charged once. Tax withholding on net share settlement is not an additional buyback benefit layered over those claims.

Liquid assets and financial claims · September 30, 2026; categories are not netted
Cash + investmentsCash + investments: $712.2M$712.2MNote principalNote principal: $1,402.5M$1,402.5MAcquisition claimsAcquisition claims: $733.9M$733.9M
Cash + investmentsCash + investments: $712.2M$712.2MNote principalNote principal: $1,402.5M$1,402.5MAcquisition claimsAcquisition claims: $733.9M$733.9M
Show the data
ItemUSD millions
Cash + investments712.22
Note principal1,402.50
Acquisition claims733.86
Common share count · Both economic classes; excludes unvested awards
December 31December 31: 227.2227.2September 30September 30: 234.4234.4November 6November 6: 234.4234.4
December 31December 31: 227.2227.2September 30September 30: 234.4234.4November 6November 6: 234.4234.4
Show the data
ItemMillions
December 31227.25
September 30234.40
November 6234.41
Date / basisBase cash $mAcquisition claims $m
2026-09-30712.2733.9
2026-11-13713.9733.9
2026-11-16956.6733.9
2026-12-31833.3608.9
2027-Q1647.9498.8
2027-Q2522.6388.7
2027-Q3397.2278.7
2027-Q4271.8168.6
2028-Q1285.2168.6
2028-Q2214.284.3
2028-Q3227.684.3
2028-Q4156.60.0

Present value and dated outcomes

The base is a ten-year economic FCFF model. Operating cash is discounted at 11.5%, with a short explicit Q4 stub and annual forecast cash through 2036. Terminal growth is 3%, supported by an assumed 18% incremental return on capital. Terminal reinvestment therefore consumes one-sixth of next-period NOPAT. That terminal formula already includes investment needs; we do not deduct a second perpetual capex amount from it.

Approximately 63% of base enterprise value comes from the terminal period. This is a material limitation. The model requires customer growth, improved gross economics and operating leverage to endure beyond the explicit horizon. Terminal dependence does not automatically make the stock overvalued, but it reduces the confidence justified by a precise-looking point estimate. Operating sensitivities and subsequent evidence matter more than superficial precision.

Base present value is $17.10 per share. Bull present value is approximately $46.54. The severe bear produces no common-equity recovery because operating losses and acquisition obligations cannot be funded on the assumed path. Its unfunded continuation arithmetic is diagnostic, not a claim that the business has a negative liquidation sale price. Common value is floored at zero. The weights are subjective: 25% severe bear, 50% base and 25% bull. The weighted current value is approximately $20.18, not an additional model or a statistical confidence interval.

The dated base value at December 31, 2027 is approximately $19.97. We value the remaining operating cash flows at that date, then add projected cash after financing and operations and subtract the debt and remaining acquisition claims. Current acquisition payments and the accrued legal payment reduce cash, and the corresponding claims are removed. There are no assumed dividends. The base total return is about 1.2%, while the bull is much higher and severe recovery is zero. The scenario-weighted future price is a separate arithmetic expectation, not a promise or a substitute for the underlying distribution.

The entry discipline is distinct from valuation: a 20% cushion below base value would be around $13.68. That is not another haircut to fair value. A stronger operating evidence set could justify a higher model before the stock ever trades there. Conversely, a lower market quote alone would not repair a deteriorating cash outlook.

Conditional December 2027 values · No distributions; scenario-specific cash and claim movements
BearBear: $0.00$0.00BaseBase: $19.97$19.97BullBull: $53.24$53.24
BearBear: $0.00$0.00BaseBase: $19.97$19.97BullBull: $53.24$53.24
Show the data
ItemUSD/share
Bear0.00
Base19.97
Bull53.24
CasePresent valueDec 2027 valueTotal returnSubjective weight
Bear$0.00$0.00−100.0%25%
Base$17.10$19.971.2%50%
Bull$46.54$53.24169.9%25%

Street context and market-implied hurdle

The dated Street reference is a $28.31 average one-year target from 15 analysts, shown by the market-data provider as updated November 11, 2026. Our own approximately $19.97 value at December 31, 2027 uses a broadly comparable horizon, about one month later. The Street aggregate can mix methods, assumptions and update times. It is useful context rather than independent confirmation of our model. Our current $17.10 fair value should not be compared with a future target as though the clocks were identical.

The reverse model asks a more specific question. Keeping the base subscriber, revenue-per-subscriber, operating-cost, investment, tax, funding and discount assumptions fixed, what gross-margin path supports the actual $19.73 quote? The answer is approximately 1.54 extra percentage points in every forecast year. Mature gross margin rises from 61% to approximately 62.54%. This is not an assertion that today's 57% margin needs only a small improvement: it is additional improvement on top of the recovery already included in our base.

The hurdle is economically plausible, but it requires evidence. A more favorable branded-product mix, retention benefits or negotiating power could support it. Continued supplier pass-through, aggressive pricing and expensive acquisition could prevent it. The reverse result is neither management guidance nor a consensus forecast.

The operating sensitivity grid changes two levers that shareholders can investigate: average subscriber scale and gross margin. A 3-point increase in margins across the forecast produces value around $22.23. A 10% increase in subscriber scale with unchanged economics produces around $19.27. These are controlled experiments, not new scenario probabilities. The rate sensitivity offers additional model-risk context, but should not distract from the observable business drivers that can make the call right or wrong.

Base versus market-implied mature gross margin · Reverse model shifts every forecast margin; all other base drivers held fixed
Base 2036Base 2036: 61.0%61.0%Market-implied 2036Market-implied 2036: 62.5%62.5%
Base 2036Base 2036: 61.0%61.0%Market-implied 2036Market-implied 2036: 62.5%62.5%
Show the data
ItemPercent
Base 203661.00
Market-implied 203662.54
Subscriber scaleMargin −3ppBase marginMargin +3pp
90%$10.24$14.93$19.54
100%$11.89$17.10$22.23
110%$13.54$19.27$24.91

Management outlook and the tests it creates

Fourth-quarter revenue guidance is $875–895 million, with adjusted EBITDA of $70–90 million. The sales midpoint is slightly below the third-quarter result. Full-year revenue guidance is $3.13–3.15 billion, and adjusted EBITDA guidance is $257–277 million. Management narrowed the sales range and reduced the EBITDA range. Guidance is a forward-looking issuer expectation, not an audited promise or a direct guide to common-owner cash.

Management described investment ahead of platform expansion and stronger marketing activity in selected international markets. The earnings-call materials also discuss broader branded-drug availability, international growth and the potential for customer experience to strengthen retention. Those initiatives can improve the long-term platform while putting pressure on near-term margins. The analytical task is to determine whether the later contribution is large enough to justify the early spending.

A useful evaluation should separate timing from economics. A membership-payment deferral can change when revenue is recognized without identical effects on cash collection. Branded-drug mix can change the margin earned on a recognized sale. Increased marketing can reduce current profit while creating either valuable retained customers or unproductive spending. All three can occur together, and a single adjusted-EBITDA figure does not distinguish them.

We would not declare success solely because the company reaches the revenue range. Subscribers, gross profit, marketing intensity, working capital and acquisition payments must support the story. Nor should one quarter of deliberate investment automatically prove failure. The next useful test is whether the following cohorts and cash measures improve as management expects. Our model allows time for improvement, but it charges the investment and funding needed to get there. The next reporting date was not independently verified for this packet and is therefore left as the next scheduled issuer release, not an invented calendar date.

Guided periodRevenue $mAdjusted EBITDA $mClassification
Q4 2026875–89570–90Management guidance
FY20263,130–3,150257–277Management guidance

Bull, bear and the stock call

The strongest bull case is that Hims becomes a more useful relationship for consumers who want convenient, supported access to multiple forms of care. Branded choices, international expansion and a broader customer base can increase the number of customers and the value of retained relationships. Lower gross margins do not automatically mean lower long-run owner cash if acquisition efficiency and repeat purchases improve enough. The bull model explicitly permits that better outcome.

The strongest bear is not simply that demand disappears. A platform can grow revenue while giving too much of the economics to manufacturers, marketing channels and other claimants. Acquisition payments can arrive before integration benefits, and stock issuance can limit the benefit per existing share. Legal and regulatory friction can affect costs, product availability, customer conversion and retention at the same time. These are mechanisms that connect to model drivers, not a generic list of frightening words.

The FTC matter involves allegations concerning privacy, subscription and cancellation practices. Hims disputes the allegations and intends to defend itself. The 10-Q lists an approximately $60 million accrual and a January 14, 2027 hearing on its motion to dismiss. The outcome, additional loss and hearing timing are uncertain. We deduct the accrued claim once and place additional legal cash only in the severe scenario. We do not present an accrual as a final settlement, a finding of guilt or a reliable ceiling on loss.

Our HOLD call means existing exposure is a high-risk judgment, while new money lacks sufficient cushion on the base. It does not mean every shareholder should take identical action regardless of portfolio or circumstances. At the reference quote, the base horizon return does not meet the stated annual requirement. Greater evidence of retention, contribution and funding control would improve the investment case; more revenue alone would not. The intended discipline is to change the model when the evidence changes, rather than choose a target because an audience wants a more optimistic rating.

Evidence that changes the thesis

The next earnings release provides the most direct operating checkpoint. Compare revenue and adjusted EBITDA with the published fourth-quarter ranges, but also track the sequence of subscriber growth, gross margin and marketing spending. A subscriber rebound is stronger evidence when it comes with better gross contribution and manageable working-capital demands. Gross-margin stabilization is more convincing when it reflects recurring mix and supplier economics rather than a one-off accounting benefit.

Acquisition settlement is an equally important catalyst for equity holders. Cash payments reduce liquidity; stock payments change ownership. Either can be sensible, but both should be reconciled against the claims already carried in the model. Future reports should make it possible to replace our assumed installment timing and financing with actual cash flows and shares. The model must then be updated without charging the same acquisition twice.

The legal calendar is a checkpoint, not a forecast of a favorable ruling. The currently disclosed January hearing could be rescheduled, and an intermediate decision might not resolve the underlying economics. We would examine both cash consequences and operational restrictions or changes in customer processes. A favorable legal development would not by itself prove the branded-product margin recovery; an adverse one should enter the relevant cash or operating driver rather than a repeated general discount.

The following signposts state what would improve or weaken the thesis. Each has a timing basis and a link to an economic consequence. The revolver expiration and note maturities deserve advance attention, even though they are not the next-quarter headline. A company with positive adjusted EBITDA can still face constrained financing flexibility. The combination of operating evidence and a funded ownership path, rather than a single catalyst announcement, determines whether the current value estimate should move.

Sources, definitions and reproducible calculation detail

Primary evidence consists of the company's Q3 2026 earnings release, its September 30 Form 10-Q, and the issuer-hosted earnings-call transcript. The regular-session quote and dated analyst aggregate are market-data inputs. Every stored source has a recorded path, URL and SHA-256 digest. The separate valuation calculation produces all scenario cash flows, present values, liquidity schedules, market-implied results and sensitivities. Financial review remains separate from merely passing the packet's technical checks.

Amounts are US dollars in millions unless otherwise stated; subscriber and share counts are in millions. Fiscal quarters refer to calendar 2026 for this issuer. Reported facts, management guidance, consensus context and author assumptions remain distinct. Revenue per average subscriber follows the company's definition, including total revenue in the numerator. Free cash flow follows the issuer's cash-flow definition when describing reported results; economic FCFF in the model is separately identified.

The cash and ownership conventions are deliberately explicit. Class A and Class V shares have the same economic rights. Existing ordinary and performance awards are included at the stated target basis, with in-the-money option proceeds. Future grants are modeled as an economic cash cost, with no second dilution charge for those same future grants. Performance awards can pay above or below target, and acquisition settlement can use stock; these uncertainties can change the actual share count. The zero-coupon convertibles remain principal claims, with capped-call net exposure accounted for rather than counting both full if-converted shares and the same debt twice.

Balance-sheet values were last reported on September 30; the valuation quote is November 13. The intervening cash bridge is an assumption informed by guidance, not a statement that unreported cash has been observed. Residual Q4 cash is forecast explicitly, financing proceeds are discounted to their assumed date, and claims are removed when paid. The model does not assume that the unused revolver or repurchase authorization is cash owned by shareholders. Severe-case negative liquidity is an unfunded diagnostic and results in zero common recovery, not a negative cash balance that could actually persist indefinitely.

Use the tables and source links to challenge the assumptions. In future reviews, compare actual subscriber growth, gross profit, investment, funding and diluted ownership with these frozen forecasts before diagnosing optimism or conservatism from stock-price movement alone. Investment returns and operating forecast accuracy are related but distinct. This research uses AI-generated analysis and voices, is educational, and is not financial advice.

Bear forecast mechanics (USD millions)

YearAverage subscribers mRevenue/sub/monthRevenueGross marginEconomic EBITCash taxCapexΔ working capitalFCFF
20272.85$983,351.654.0%−301.60.0117.34.2−439.4
20282.90$983,410.454.0%−259.20.0119.41.2−334.5
20293.00$993,564.055.0%−178.20.0124.73.1−216.9
20303.10$1003,720.055.0%−145.10.0130.23.1−185.4
20313.20$1013,878.456.0%−62.10.0135.73.2−104.0
20323.30$1024,039.256.0%−20.20.0141.43.2−63.8
20333.40$1034,202.456.0%29.47.4147.13.3−23.2
20343.50$1044,368.056.0%78.619.7152.93.312.0
20353.60$1054,536.056.0%122.530.6158.83.443.1
20363.70$1064,706.456.0%141.235.3164.73.455.4

Base forecast mechanics (USD millions)

YearAverage subscribers mRevenue/sub/monthRevenueGross marginEconomic EBITCash taxCapexΔ working capitalFCFF
20273.15$1053,969.057.0%19.85.0158.816.6−61.2
20283.55$1064,515.658.0%176.144.0180.610.953.4
20293.95$1075,071.859.0%360.190.0202.911.1182.9
20304.35$1085,637.660.0%552.5138.1225.511.3318.5
20314.75$1096,213.061.0%776.6194.2248.511.5477.8
20325.15$1106,798.061.0%951.7237.9271.911.7600.1
20335.50$1117,326.061.0%1,106.2276.6293.010.6709.2
20345.80$1127,795.261.0%1,255.0313.8311.89.4815.0
20356.05$1138,203.861.0%1,394.6348.7328.28.2914.8
20366.30$1148,618.461.0%1,508.2377.1344.78.3993.6

Bull forecast mechanics (USD millions)

YearAverage subscribers mRevenue/sub/monthRevenueGross marginEconomic EBITCash taxCapexΔ working capitalFCFF
20273.40$1084,406.459.0%211.552.9198.325.345.2
20284.10$1105,412.061.0%530.4132.6243.520.1269.4
20294.80$1126,451.263.0%916.1229.0290.320.8537.2
20305.50$1147,524.064.0%1,324.2331.1338.621.5821.2
20316.20$1168,630.465.0%1,760.6440.2388.422.11,125.7
20326.90$1189,770.465.0%2,139.7534.9439.722.81,386.6
20337.50$11910,710.065.0%2,463.3615.8481.918.81,614.5
20348.00$12011,520.065.0%2,753.3688.3518.416.21,818.4
20358.45$12112,269.465.0%3,042.8760.7552.115.02,021.7
20368.85$12212,956.465.0%3,303.9826.0583.013.72,205.0
SourceDescription
releaseIssuer Q3 results and management outlook
10qFinancial statements, acquisitions, notes, ownership and risks
transcriptIssuer-hosted earnings-call discussion
quoteNov13 regular-session close
streetNov11 analyst aggregate and horizon
Reported inputValueUnitPeriodEvidence
revenue890.373USD millionsQ3 2026release
gross profit509.199USD millionsQ3 2026release
gross margin57percentQ3 2026release
net loss−33.04USD millionsQ3 2026release
operating loss−66.146USD millionsQ3 2026release
marketing247.28USD millionsQ3 2026release
sbc64.477USD millionsQ3 2026release
ebitda82.388USD millionsQ3 2026release
ocf65.393USD millionsQ3 2026release
fcf25.974USD millionsQ3 2026release
domestic657.089USD millionsQ3 2026release
international233.284USD millionsQ3 2026release
subscribers2.788million subscribersQ3 2026release
arpu105USD per average subscriber per monthQ3 2026release
prior revenue598.976USD millionsQ3 2025release
prior gross profit442.058USD millionsQ3 2025release
prior gross margin74percentQ3 2025release
prior fcf79.364USD millionsQ3 2025release
prior marketing232.15USD millionsQ3 2025release
prior sbc40.172USD millionsQ3 2025release
prior subscribers2.471million subscribersQ3 2025release
prior arpu81USD/subscriber/monthQ3 2025release
ytd revenue2251.691USD millions9M ended September 30, 202610q
ytd ocf118.81USD millions9M ended September 30, 202610q
ytd fcf10.813USD millions9M ended September 30, 202610q
ytd capex107.997USD millions9M ended September 30, 202610q
ytd sbc143.455USD millions9M ended September 30, 202610q
ytd capitalized sbc6.8USD millions9M ended September 30, 202610q
ytd repurchase0USD millions9M ended September 30, 202610q
ytd option proceeds13.282USD millions9M ended September 30, 202610q
ytd tax withholding cash81.232USD millions9M ended September 30, 202610q
ytd net issuance7.152577million shares9M ended September 30, 202610q
cash605.604USD millionsSeptember 30, 202610q
investments106.617USD millionsSeptember 30, 202610q
debt face1402.5USD millionsSeptember 30, 202610q
debt carrying1367.393USD millionsSeptember 30, 202610q
acquisition claims733.864USD millionsSeptember 30, 202610q
acquisition current565.233USD millionsSeptember 30, 202610q
legal accrual60USD millionsSeptember 30, 202610q
lease liabilities193.363USD millionsSeptember 30, 202610q
receivables427.847USD millionsSeptember 30, 202610q
payables515.69USD millionsSeptember 30, 202610q
rsus19.178million sharesSeptember 30, 202610q
repurchase authorization remaining225USD millionsSeptember 30, 202610q
shares latest234.412422million sharesNovember 6, 202610q
shares sept234.398098million sharesSeptember 30, 202610q
shares dec227.245521million sharesDecember 31, 202510q
revenue fy guide[3130, 3150]USD millionsFY2026release
ebitda fy guide[257, 277]USD millionsFY2026release
revenue q4 guide[875, 895]USD millionsQ4 2026release
ebitda q4 guide[70, 90]USD millionsQ4 2026release
international guide650USD millionsFY2026 minimumtranscript
eucalyptus purchase968.539USD millionsJune 2026 acquisition10q
eucalyptus share revenue15percentQ3 2026 approximately10q
price19.73USD/share2026-11-13T16:00:00-05:00quote
street28.31USD/shareUpdated November 11, 2026; one-year horizonstreet